Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pier 70 Ventures is a venture capital firm founded in 2020 by former Boeing executives, based in Seattle, Washington. The firm also operates in Indianapolis, New York, and San Francisco, focusing on early-stage companies that are innovating in healthcare. Pier 70 Ventures aims to empower entrepreneurs by providing not only capital but also mentorship and access to a global network of industry experts.
The firm emphasizes investments in companies that are patient-centric, wellness-focused, data-driven, connected, cloud-based, and AI-enabled. Pier 70 Ventures is committed to generating financial returns while contributing to societal change and economic benefits. The firm operates under the belief that diverse leadership teams drive superior financial outcomes, aligning with their investment thesis.
Pier 70 Ventures invests in early-stage healthcare innovation, specifically targeting companies that are shaping the future of health. Their investment strategy emphasizes diverse teams and technologies that are patient-centric and wellness-focused. The firm primarily invests in sectors such as healthcare, digital health, and AI, with a geographic focus on North America.
The firm typically invests at the pre-seed, seed, and seed-plus stages, with initial check sizes ranging from $250,000 to $2 million and follow-on investments between $2 million and $5 million. Pier 70 Ventures seeks to build a portfolio of 16 to 22 companies per fund, focusing on impact-driven innovation that generates financial returns while fostering societal change.
Pier 70 Ventures has a diverse portfolio of 16 companies, primarily in the healthcare sector. Notable portfolio companies include:
This portfolio reflects Pier 70 Ventures' commitment to investing in companies that leverage technology to improve health outcomes and drive innovation in the healthcare sector.
R. Miller Adams - Managing Partner: Co-founder of Pier 70 Ventures, R. Miller Adams has extensive experience in corporate venture capital, having co-developed Boeing's venture capital arm, which grew to a $250 million fund-of-funds.
Preetha Ram, Ph.D. - Managing Partner: Preetha brings a strong background in healthcare and technology, focusing on innovative solutions that enhance patient care.
Shaun Hawkins - Managing Partner: Shaun has a background in healthcare strategy and diversity initiatives, contributing to the firm's focus on diverse leadership.
Robert (Bob) H. Balk - Managing Partner: Bob co-developed Boeing's VC arm alongside R. Miller Adams, bringing significant corporate venture expertise to the firm.
Leisl Kleindl-Schelling, CPA - Chief Financial Officer: Leisl oversees financial operations and strategy, ensuring the firm's fiscal health.
Meg O'Conor - Director, Communications: Meg manages the firm's communications strategy and public relations efforts.
Leland Melvin - Venture Partner: Leland provides insights from his extensive experience in technology and innovation.
Jenn Bennett - Venture Advisor: Jenn advises on healthcare investments, leveraging her industry expertise.
Stephanie Bousheri - Venture Advisor: Stephanie offers guidance on market trends and investment opportunities.
Jeff Geng, Ph.D. - Venture Advisor: Jeff specializes in healthcare technology and innovation.
Frederick W. Grimm - Venture Advisor: Frederick provides insights into healthcare market dynamics.
Dennis Liotta - Venture Advisor: Dennis advises on therapeutic development and healthcare investments.
To pitch Pier 70 Ventures, founders should visit their website at pier70ventures.com and submit their information through the contact form. A well-structured pitch deck should include details about the team, market opportunity, and the technology's impact on healthcare.
Founders can also email their pitch directly to team@pier70ventures. The firm prefers warm introductions but is open to direct submissions. Response times may vary, but founders can expect feedback within a few weeks.
In 2022, Pier 70 Ventures launched its INpact Fund, focusing on early-stage healthcare companies led by diverse teams. This initiative aligns with their mission to drive impactful change in the healthcare sector.
In early 2023, the firm announced investments in several innovative healthcare startups, further expanding its portfolio and reinforcing its commitment to supporting diverse leadership in healthcare innovation.
What are Pier 70 Ventures' investment criteria?
Pier 70 Ventures focuses on early-stage companies in healthcare, digital health, and AI sectors. They prioritize diverse leadership teams and patient-centric innovations.
How can I pitch to Pier 70 Ventures?
Founders can pitch by visiting their website at pier70ventures.com or by emailing their team at team@pier70ventures. A clear presentation of the business model, market opportunity, and team diversity is essential.
What makes Pier 70 Ventures different from other VCs?
Pier 70 Ventures emphasizes the importance of diverse leadership teams, believing that diversity drives superior financial returns. Their focus on impact-driven healthcare innovation sets them apart.
What is the typical check size for investments?
Initial investments range from $250,000 to $2 million, with follow-on investments between $2 million and $5 million, depending on the growth and needs of the portfolio companies.
What is the geographic focus of Pier 70 Ventures?
The firm primarily invests in North America, targeting early-stage healthcare companies across various locations, including Seattle, Indianapolis, New York, and San Francisco.
What type of support do portfolio companies receive?
Pier 70 Ventures provides mentorship, strategic guidance, and access to a global network of industry experts, helping portfolio companies navigate challenges and scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.